Compare Sony Group Corp (SONY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Sony Group Corp trades at $24.24 (market cap $136.87B), while State Street SPDR S&P Biotech ETF trades at $154.35 (market cap $10.11B). The key difference: Sony Group Corp is far larger — about 13.5× State Street SPDR S&P Biotech ETF's market cap, and Sony Group Corp pays a 0.66% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sony Group Corp for 96 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| SONY | XBI | |
|---|---|---|
Market Cap | $136.87B | $10.11B |
Volume | 5,364,503 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $30.26 | $169.55 |
52-Week Low | $19.32 | $104.99 |
Typical Hold Time | 96 Days | 37 Days |
Enterprise Value | $134.77B | — |
Dividend Yield | 0.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony trades at $24.05, up 2.25% with mixed technical signals and neutral analyst sentiment. The company reported strong Q2 2026 earnings beat but faces profitability challenges with negative net income margin and ROE. Recent news highlights Sony's content strength and legal actions against AI companies for copyright infringement.
Sony presents a mixed investment case with strong cash flow generation and content portfolio offset by near-term profitability concerns. The stock's valuation appears reasonable with P/E of 20.34, but investors should monitor the company's ability to improve margins amid competitive pressures.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
